What are the long‑term risks and benefits of transdermal patch versus oral tablet hormone replacement therapy (HRT) based on recent research, such as the Washington Post article on FDA changes?

Long-Term HRT: Transdermal Patches Are Safer Than Oral Pills

For long-term hormone replacement therapy, transdermal estradiol patches are strongly preferred over oral formulations due to significantly lower risks of venous thromboembolism, stroke, and potentially breast cancer, while maintaining equivalent benefits for symptom relief and bone protection.

Key Safety Differences Between Routes

Venous Thromboembolism Risk

The most clinically significant difference between routes is VTE risk. Oral estrogen increases VTE risk by 58-63% compared to no use, while transdermal preparations show no increased risk 1, 2. This difference is consistent across multiple large observational studies and represents the clearest evidence distinguishing the two routes 3.

• Oral estrogen + progestin: RR 2.03 for VTE 4
• Transdermal estrogen: RR 0.93 (not statistically significant) 1

Stroke Risk

Oral preparations carry higher stroke risk, particularly concerning for women over 60:

• Oral combined HRT increases stroke risk by 39% 4
• Transdermal estradiol at doses ≤50 μg does not increase stroke risk 5

Cardiovascular Considerations

Neither route is indicated for cardiovascular prevention 6. However, transdermal estradiol avoids first-pass hepatic metabolism, resulting in:

• No increase in coagulation factors
• No elevation of C-reactive protein
• Lower impact on triglycerides 7

Breast Cancer Risk Varies by Formulation

Combined Therapy (Estrogen + Progestogen)

• Oral combined therapy increases breast cancer risk by 27% after 5.6 years 4
• The type of progestogen matters significantly: Micronized progesterone appears safer than synthetic progestins 5
• Low-dose transdermal estradiol + progestin may mitigate breast cancer risk 8

Estrogen-Only Therapy (Post-Hysterectomy)

• Estrogen-only therapy shows neutral to favorable breast cancer profile 6
• May actually reduce breast cancer risk by 16% 8

Optimal Formulations Based on Recent Evidence

For Women With Intact Uterus

Use transdermal 17β-estradiol (not conjugated equine estrogen) with micronized progesterone 5, 6:

• Start with low-dose transdermal patches (50-100 μg)
• Add micronized progesterone (not medroxyprogesterone acetate)
• This combination minimizes VTE, stroke, and breast cancer risks

For Women Post-Hysterectomy

Use transdermal estradiol alone:

• Provides symptom relief without increased breast cancer risk
• Reduces fracture risk by 27% 4
• Avoids VTE risk associated with oral preparations

Duration and Timing Considerations

Age and Timing Matter

The "timing hypothesis" is critical 6:

• Initiate within 10 years of menopause onset for optimal benefit-risk ratio
• Women starting HRT after age 60 or >10 years post-menopause face higher cardiovascular risks
• Most guideline evidence comes from older women (average age 63), limiting applicability to younger menopausal women 9

Duration Guidelines

Traditional recommendations to use "lowest dose for shortest time" are evolving 9:

• Recent 2024 Medicare data shows continued benefits beyond age 65 with appropriate formulations 8
• For women starting HRT young (<45 years), continuation until natural menopause age (51 years) is reasonable 10, 11
• Beyond age 51, reassess annually based on individual risk factors

Absolute Risk Perspective

The absolute risks remain modest even with oral therapy 9, 12:

• Per 10,000 women taking oral combined HRT for 1 year:
  • 7 additional CHD events
  • 8 additional strokes
  • 8 additional pulmonary emboli
  • 8 additional breast cancers
  • BUT: 6 fewer colorectal cancers and 5 fewer hip fractures

With transdermal preparations, the VTE and stroke excess risks are eliminated while maintaining fracture benefits 1, 2.

Critical Pitfalls to Avoid

1. Don't prescribe oral estrogen to women with VTE risk factors (obesity, thrombophilia, immobility) - always use transdermal 7

2. Avoid medroxyprogesterone acetate - it carries the highest VTE risk (RR 2.10) compared to other progestogens 1

3. Don't use conjugated equine estrogen when estradiol is available - estradiol has lower VTE risk (RR 0.83-0.85 vs CEE) 1

4. Don't continue oral HRT in women who develop hypertension, diabetes, or metabolic syndrome - switch to transdermal 7

5. Don't assume all transdermal doses are equivalent - doses >50 μg may increase stroke risk 5

Recent FDA Context

While the provided evidence doesn't include the specific Washington Post article referenced, recent regulatory focus has emphasized:

• Route-specific risk profiles (transdermal vs oral)
• Progestogen type selection (progesterone vs synthetic progestins)
• Individualized risk assessment rather than blanket restrictions

The evidence strongly supports transdermal estradiol with micronized progesterone as the safest long-term HRT regimen, particularly for women requiring therapy beyond 5 years or those with metabolic/thrombotic risk factors 8, 3, 1, 5, 6.